医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

AMCo acquires Australian company Boucher and Muir

2015年07月14日 PM11:41
このエントリーをはてなブックマークに追加


 

LONDON

The British-based international niche pharmaceutical business AMCo has acquired the Australian pharmaceutical company, Boucher and Muir (‘BNM’).

BNM was set up in 1957 and has grown to become a highly successful company with sales in Australia, New Zealand and the Pacific Islands. BNM sells medical products from vaccines to anaesthetics, as well as more typical products such as solid dose tablets and capsules. It also works closely with government health departments in the Pacific Islands. It has an excellent reputation for quality and reliability. AMCo and BNM have been working together for the past ten years, as BNM is one of AMCo’s main distributors for medicines in the region.

The acquisition of BNM is in keeping with AMCo’s strategy of international expansion into key territories. It will allow AMCo to create a regional commercial centre in Australia, along similar lines to the Nordics regional centre that AMCo created when it acquired Abcur AB in Sweden in December 2013. Earlier this year AMCo created a further regional centre in Dubai to serve the MENA region.

John Beighton, Chief Executive Officer of AMCo said: “Boucher and Muir has been our trusted partner in the Australasian region for the past decade and we are pleased to be able to acquire the company. It has a strong history of supplying niche medicines in the region and we will be looking to build on that as a cornerstone of AMCo’s expansion in Australia, New Zealand and the surrounding geographies.”

David Frish, Managing Director of BNM said: “We have had a great partnership with AMCo for the past decade and we are delighted to become part of the AMCo family. I look forward to working more closely with them as part of the team, and to bringing more AMCo niche medicines into the local market.”

AMCo currently sells its products in 112 territories worldwide. Since the acquisition of Fucithalmic® from LEO Pharma in April 2013, AMCo has acquired or set up commercial platforms in Ireland, France, Sweden, Benelux, Italy, Dubai and now Australia. AMCo has also established presence in South Africa, Hong Kong and Argentina to manage its regional African, AsiaPac and Latin America businesses respectively.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150714006169/en/

CONTACT

AMCo
For images and interviews please contact:
Anne
Cantelo
Onyx
E: anne@onyx-pr.com
T:
020 7048 2700
Out of office hours: 07789 905304

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表